| Literature DB >> 2609918 |
S Bertoglio1, G Melioli, E Baldini, A Catturich, M R Sertoli, D Civalleri, P Percivale, W Meier, A Galazka, F Badellino.
Abstract
In a phase-I-study recombinant interleukin-2 (rIL-2) in a dose from 0.01 to 0.3 mg/m2/day for 7 to 14 days was infused intraperitoneally. Side effects were fever and fluid retention. 2 patients showed a bacterial peritonitis after paracentesis. The investigations showed that the intraperitoneal (i.p.) administration of interleukin-2 activates the whole lymphokine cascade.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2609918
Source DB: PubMed Journal: Acta Med Austriaca ISSN： 0303-8173